
    
      The study consisted of a screening period (up to 2-week period from screening to
      randomization), a 24-week double-blind treatment period with placebo or idalopirdine 30
      mg/day or 60 mg/day as adjunctive therapy to donepezil 10 mg/day, and a 4-week safety
      follow-up period following study completion or withdrawal from treatment.
    
  